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Abstract
Prenatal diagnosis of congenital anomalies provides valuable information and allows 
proper management of pregnancy and delivery. The common congenital anomalies are 
cardiovascular anomalies, congenital anomalies of the central nervous system, fetal tho-
racic anomalies, abdominal wall defects, kidney and urinary tract defects, and esopha-
geal, gastrointestinal, and anorectal abnormalities. Different defects require particular 
assessment, evaluation and care. Pregnancy management mainly includes detection of 
the malformations, genetic assessment, ultrasound follow-ups and evaluation of fetal 
well-being as well as performing various invasive or non-invasive procedures. Managing 
delivery is also highly important and fetal anomaly specific. The main aspects of deliv-
ery management discussed in this chapter are delivery place, timing, route and delivery 
room care.
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1. Introduction
Prenatal diagnosis of congenital anomalies provides parents an opportunity to obtain prog-
nostic information prior to birth, learn about treatment options before and after delivery, 
reach decisions concerning the management approach that is best for their family (e.g., 
whether to terminate pregnancy or undergo in utero intervention, if available; noninterven-
tion), and plan for specific needs at birth [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Cardiovascular anomalies
Identification and management of fetal cardiac abnormalities are important because congeni-
tal anomalies are the leading cause of infant death and congenital heart disease accounts for 
30–50% of these deaths [1]. The best time for evaluating the fetal heart anatomy is 18–22 weeks 
of gestation, because the fetal cardiac anatomy can be visualized well at this stage of preg-
nancy, a complete fetal anatomic survey can be performed, and there is time for further evalu-
ation (e.g., echocardiogram, chromosomal microarray), if indicated, while the fetus is still 
periviable [2]. After 30 weeks of gestation, it can be difficult to obtain good images as the 
fetus becomes more crowded within the amniotic cavity. Fetal arrhythmias, myocarditis, car-
diomyopathy, heart failure, valvular insufficiency or obstruction and cardiac tumors have 
variable onset. Fetal echocardiography should be performed in fetuses at a higher risk of 
congenital heart disease (Table 1).
Indications with higher risk profile (estimated >2% absolute risk) Indications with lower risk profile 
(estimated >1 and <2% absolute risk)
- Maternal pregestational diabetes mellitus or diabetes mellitus 
diagnosed in the first trimester
- Maternal phenylketonuria (uncontrolled)
-  Maternal autoantibodies (SSA/SSB), especially if a previous child had 
SSA/SSB-related heart disease
-  Maternal cardiac teratogens (e.g., thalidomide, angiotensin-
converting enzyme [ACE] inhibitor, retinoic acid, nonsteroidal anti-
inflammatory drugs [NSAIDs] in the third trimester)
-  Maternal first trimester rubella infection
-  Maternal infection with suspicion of fetal myocarditis because of 
poor contractility or effusions on standard four-chamber cardiac 
examination (e.g., coxsackie virus, adenovirus, cytomegalovirus)
-  Pregnancy conceived by assisted reproduction technology (ART)
-  Congenital heart disease in first-degree relative of fetus (maternal, 
paternal or sibling)
-  Disorder of first- or second-degree relative with Mendelian 
inheritance with congenital heart disease association (e.g., Noonan, 
tuberous sclerosis, Holt-Oram, velocardiofacial [DiGeorge] 
syndrome/22q11 deletion, Alagille syndrome, Williams syndrome)
-  Fetal cardiac abnormality (structural, functional, arrhythmia) 
suspected on obstetrical ultrasound
-  Fetal noncardiac abnormality suspected on obstetrical ultrasound
-  Fetal chromosome testing reveals a genetic mutation, deletion, 
rearrangement, or aneuploidy
-  Fetal tachycardia or bradycardia or frequent or persistent irregular 
heart rhythm
-  Fetal increased nuchal translucency >95 percentile (≥3 mm) on first 
trimester ultrasound
-  Monochorionic twinning
-  Fetal hydrops or effusions
-  Maternal medications (anticonvulsants, 
lithium, vitamin A, paroxetine, NSAIDs in 
first/second trimester)
-  Congenital heart disease in second-degree 
relative of fetus.
-  Fetal abnormality of the umbilical cord 
or placenta (e.g., single umbilical artery, 
agenesis of the ductus venosus)
-  Fetal intra-abdominal venous anomaly
Table 1. Indications for fetal echocardiography [2].
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2.1. Pregnancy management
When a fetal cardiac abnormality is detected, additional evaluation and follow-up are 
indicated.
• Assessment for extracardiac anomalies. The extracardiac abnormalities are detected in 
20–40% of all fetal cardiac anomalies [1, 3]; the cardiac anomalies are part of numerous 
fetal syndromes [4]. A systematic review and meta-analysis of studies of prenatal ultra-
sound and magnetic resonance imaging (MRI) found that brain abnormalities, delay in 
head growth, and brain-sparing were observed in subgroups of fetuses with congenital 
heart disease [5] However, the prognostic significance of these findings was unclear.
• Genetic assessment. Fetal genetic assessment is indicated because chromosome abnormali-
ties are common in fetuses with cardiac defects, even when isolated [6]. Forty-one percent 
of fetuses with prenatally diagnosed structural cardiac defects had an abnormal karyotype 
[7]. The incidence in infants of congenital heart disease about 15% [6], it is higher because of 
in utero mortality in many cases, such as the lethal autosomal trisomies (e.g., trisomy 9 or 
16). The risk of fetal aneuploidy varies depending on the malformation. For example (risk 
percent, [2]): atrioventricular septal defect (46–73%), truncus arteriosus (19–78%), double-
outlet right ventricle/conotruncal malformations (6–43%), coarctation/arch interruption 
(5–37%), tricuspid valve dysplasia (including Ebstein malformation, 4–16%), tetralogy of 
Fallot (7–39 percent), hypoplastic left heart syndrome (HLHS, 4–9%), pulmonic stenosis/
atresia with intact septum (1–12%), and transposition of great arteries (0%).
• Ultrasound follow-up. The necessity, timing, and frequency of serial assessment should 
be guided by the nature and severity of the lesion, presence of heart failure, anticipated 
timing and mechanism of progression, and the options available for prenatal and post-
partum intervention [2]. At least one follow-up examination early in the third trimester 
is reasonable in order to look for abnormalities that progressed in severity or may not 
have been detectable earlier in gestation and have peripartum clinical implications. Some 
causes of progressive fetal cardiac dysfunction include worsening valvular insufficiency 
or obstruction, increasing obstruction to blood flow in the great arteries, and develop-
ment or worsening of myocarditis or cardiomyopathy, arrhythmias, or cardiac tumors 
[2]. Intrauterine fetal growth restriction is more prevalent in these fetuses with congenital 
heart disease [8].
• Referral to a pediatric cardiologist. The purpose is to educate the patient about the sus-
pected diagnosis and discuss management options before and after delivery, including the 
preferred site for delivery [1].
• Evaluation of fetal well-being. Fetuses with cardiac structural anomalies, functional dis-
orders, or arrhythmias that have the potential to compromise tissue oxygen delivery are 
generally followed with antepartum testing, with intervention if results are abnormal. In 
one retrospective cohort study, fetuses with a genetic syndrome, extracardiac anomaly, or 
severe valvular regurgitation were at increased risk for fetal demise: 15/197 (7.6%) fetuses 
with one or more of these risk factors died in utero versus 3/270 (1%) fetuses without any 
of these risk factors [9]. Six of the 22 fetal deaths occurred at 20–23 weeks and 16 occurred 
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at 26–41 weeks (including three deaths at 37, 39, and 41 weeks). However, there is no strong 
evidence of the value of this practice and antepartum fetal testing with the nonstress test, 
biophysical profile, or fetal movement count has not been tested specifically in this clinical 
setting. The type of test depends on the underlying abnormality; for example, the biophysi-
cal profile is particularly useful in fetuses with arrhythmias and provides an opportunity 
to monitor for development or progression of hydrops in any fetus with severely altered 
hemodynamics.
• Fetal therapy. Transplacental medical therapy can improve the prognosis of some fetal 
arrhythmias [1]. Invasive in utero cardiac intervention (aortic or pulmonary balloon val-
vuloplasty, atrial needle septoplasty) may improve the prognosis of some lesions, such as 
HLHS or severe valvular abnormalities (severe mitral regurgitation, aortic stenosis, pul-
monary atresia). Current evidence on the effectiveness of prenatal intervention for CHD 
derives mostly from case reports and a few larger series; although the results of the meta-
analysis are encouraging in terms of perinatal survival, they should be interpreted with 
caution when comparing with procedures performed after delivery [10].
2.2. Delivery management
• Delivery place. Delivery should be planned at a facility with the appropriate level of care 
for the mother and neonate. Neonates with ductal-dependent lesions and most with criti-
cal cardiac lesions should be delivered at a facility with a level III NICU and pediatric 
cardiology expertise. If this is not feasible, transport arrangements should be established in 
advance of delivery [1].
Specialized delivery room care is 
recommended for fetuses with:
-  d-transposition of the great arteries
-  sustained or uncontrolled tachyarrhythmias with heart failure or hydrops 
fetalis
Specialized delivery room care 
planning is reasonable for fetuses 
with:
-  hypoplastic left heart syndrome (HLHS) with restrictive or intact atrial septum 
and abnormal pulmonary vein flow (pulmonary vein forward/reversed flow 
ratio < 3) or abnormal hyperoxia test in the third trimester
-  complete heart block and low ventricular rate, cardiac dysfunction, or hydrops 
fetalis
Specialized delivery room care 
planning may be considered in 
fetuses with:
-  tetralogy of Fallot with absent pulmonary valve
-  Ebstein anomaly with hydrops fetalis
-  total anomalous pulmonary venous return, obstructed
Specialized delivery room care is 
not needed for fetuses with:
-  mild tetralogy of Fallot, ventricular septal defect, atrioventricular septal defect
-  shunt lesions
-  most ductal-dependent lesions, but initiation of prostaglandin E1 may be 
indicated in neonatal intensive care unit
-  controlled arrhythmias
Table 2. Need for specialized delivery room care in specific anomalies.
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• Timing and route. Cesarean delivery is performed for standard obstetrical indications, as 
there is no evidence that route of delivery of fetuses with congenital heart disease affects 
outcome [11]. Based on observational data, induction of labor or scheduled cesarean before 
39 weeks of gestation is not recommended in the absence of standard maternal or fetal 
concerns about well-being, as even early term delivery has been associated with worse out-
comes after neonatal cardiac surgery [2, 12]. One exception may be single ventricle defects, 
where earlier delivery may be beneficial [13].
• Delivery room care. Risk assessment for anticipated compromise in the delivery room or 
during the first few days of life is disease-specific (Table 2, [2]).
3. Congenital anomalies of the central nervous system (CNS)
Malformations of the central nervous system (CNS) are among the most common types of 
major congenital anomalies. Ultrasound examination is an effective modality for prenatal 
diagnosis of these anomalies. Poor timing of the examination, rather than poor sensitivity, 
can be an important factor in failing to detect a CNS abnormality [14]. Ideally, pregnancies at 
increased risk of fetal CNS anomalies and those with suspicious findings on a basic examina-
tion should undergo fetal neurosonography performed by clinicians with expertise in this 
area. Magnetic resonance imaging (MRI) is an option for further evaluation in cases of diag-
nostic uncertainty when additional information will influence subsequent management of the 
pregnancy [15].
3.1. Holoprosencephaly
Holoprosencephaly is a fetal anomaly that cannot be altered or treated. Elective termination 
of pregnancy is recommended if the diagnosis is made early (till 22–24 weeks of gestation 
under the pregnancy termination law in different countries). Because approximately 30–50% 
of fetuses with this anomaly have chromosomal abnormalities, prenatal karyotype is recom-
mended. A family history (the familial recurrences have been reported), the history of current 
pregnancy (exposure to ethanol, salicylates) should be obtained, the evaluation for cytomega-
lovirus should be done. If the parents choose the conservative management, there is no fetal 
intervention for this condition and the cesarean delivery should be considered only for mater-
nal indications [16].
3.2. Agenesis of the corpus callosum
During routine screening for fetal anomalies at 20–22 weeks of gestation, the two most impor-
tant clues that the corpus callosum needs further assessment to exclude a callosal abnormality 
are (1) non-visualization of the cavum septi pellucidi and (2) ventriculomegaly (lateral ventri-
cles measuring >10 mm). The cause of this anomaly may be genetic, infectious (TORCH infec-
tions and Zika virus), vascular, or toxic (alcohol—fetal alcohol syndrome). Callosal  dysgenesis 
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was isolated in only 24% of the fetuses, and isolated callosal abnormalities are associated with 
normal neurodevelopmental outcome in approximately two-thirds of fetuses [17].
3.2.1. Pregnancy management
• Genetic assessment. Genetic factors are most common. Among the genetic causes, “syn-
dromic” diagnosis is made in 30–45% of cases and a monogenic cause can be identified 
in 20–35%. Over 200 genetic syndromes, many of which may have variable phenotype, 
include disorder of the corpus callosum as a feature.
• Magnetic resonance imaging (MRI) is most helpful after the 20th week of gestation, since 
about 20% of apparently isolated cases diagnosed by ultrasound have associated CNS 
anomalies on MRI [18].
• Evaluation of fetal well-being. If an isolated agenesis of corpus callosum is detected and 
the chromosomes are normal, the usual standard pregnancy management should be 
recommended.
3.2.2. Delivery management
Vaginal delivery is recommended unless is significant hydrocephalus with macrocephaly. 
Delivery prior to term is not advisable [16].
3.3. Dandy-Walker malformation
‘Isolated’ Dandy-Walker malformation (DWM) in the light of recent literature, which has 
demonstrated a potential good clinical and intellectual outcome of fetuses presenting with 
DWM characterized by partial vermian agenesis and absence of associated anatomical anom-
alies [19].
3.3.1. Pregnancy management
• Assessment for associated CNS and extra-CNS anomalies. The presence of the additional 
anomalies adversely affects survival and prognosis for the infant and child with DWM. The 
risk of associated intracranial anomalies appears to be 20–60%, and in this situation, the 
mental retardation and perinatal mortality are increased [16].
• Genetic assessment. In the syndromic form of DWM, malformations of the heart, face, limbs, 
or gastrointestinal or genitourinary system may be present. DWM may occur as part of a 
Mendelian disorder (e.g., Meckel syndrome), a chromosomal aneuploidy (e.g., 45X, trip-
loidy), environmental exposures (e.g., rubella, alcohol), a multifactorial etiology (e.g., con-
genital heart defect, neural tube defects), or as a sporadic defect (e.g., holoprosencephaly).
• Evaluation of fetal well-being. The option for elective termination of pregnancy is offered 
for parents if the diagnosis of DWM with associated CNS anomalies is made early. If the 
diagnosis is made in the third trimester, conservative management is recommended. In 
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most cases, the cyst, ventricular dilatation, and cisterna magna enlargement occur slowly, 
rarely severe or rapidly increasing ventriculomegaly needs for obstetrical intervention [16]. 
There is no fetal intervention for DWM.
3.3.2. Delivery management
The cesarean delivery should be considered only for maternal indications.
3.4. Anencephaly
3.4.1. Pregnancy management
Anencephaly is the most common neural tube defect (NTD) [20]. The anencephalic fetus 
can be definitively identified by the 12th postmenstrual week by TVS; although in some 
cases, this diagnosis has been made as early as 9–10 postmenstrual weeks [21]. Early diag-
nosis can be made if the cranium is examined carefully at the time of nuchal translucency 
measurement [22].
Up to 75% of anencephalic infants are stillborn. Liveborn infants generally die within hours 
but occasionally survive for a few days or weeks. There are no neurosurgical management 
options. In most developed countries where abortion is legal, these pregnancies are inter-
rupted earlier [23]. Because of their poor prognosis, anencephalic infants have been considered 
as potential organ donors for transplantation. The clinical cases reported that anencephalic 
infants are not good candidates for organ donation because they do not generally meet cri-
teria for brain death until their clinical condition has declined to the point where the solid 
organs are damaged [24]. Polyhydramnios develops in up to 50% of the cases during the 
second and third trimester due to decreased fetal swallowing, but is not present during the 
first trimester [20].
Prevention is the most important aspect of management of anencephaly. Periconceptional folic 
acid supplementation is recommended for all women who are pregnant or who may become 
pregnant. Higher doses of folic acid supplements are usually recommended for women who 
are taking anticonvulsant drugs or who have had a previous pregnancy affected by a NTD.
3.4.2. Management of labor
Because polyhydramnios is often associated with this condition, the rate of premature labor 
is increasing. Labor and delivery are frequently associated with an unstable fetal position, 
dystocia of labor, placental abruption, and postpartum hemorrhage. The cesarean delivery 
should be considered only for maternal indications.
3.5. Exencephaly
Exencephaly has been detected as early as the 10th postmenstrual week. In the second tri-
mester, the usual appearance of the cranium encasing the brain is lost. The exposed brain has 
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a heterogeneous appearance and is not covered by the cranium. Although the cranial vault 
is absent, the fetal facial bones can be clearly visualized. Maternal serum alpha-fetoprotein 
levels are highly elevated.
3.5.1. Pregnancy management
Exencephaly is a lethal condition, the termination of pregnancy should be recommended 
for parents. Typically, exencephaly is not associated with chromosomal abnormalities, but, 
because of the severity of the defect, a chromosome analysis should be performed to permit 
accurate genetic counseling [16].
3.5.2. Delivery management
The cesarean delivery should be considered only for maternal indications. There are no indi-
cations for resuscitation of the newborn.
3.6. Encephalocele
3.6.1. Pregnancy management
Encephalocele can be diagnosed at 11–14 weeks during sonographic screening for aneuploidy.
• Genetic assessment. Cephalocele usually occurs as an isolated lesion, but may be a part of 
a syndrome such as Meckel (or Meckel-Gruber) or Walker-Warburg syndrome in a small 
percentage of cases. Both syndromes are autosomal recessive.
• Assessment for associated anomalies. Detailed sonography or MRI should be performed to 
verify the diagnosis and to search for associated anomalies.
Obstetrical management depends on the size of defect, the gestational age at diagnosis, and 
the presence or absence of associated anomalies. Prognosis depends on (1) the presence and 
amount of brain in the herniated sac (this is the most important consideration) and (2) the 
presence or absence of hydrocephalus, microcephaly, and other anomalies. If the encephalo-
cele is diagnosed at less than 22–24 weeks of gestation, the termination of the pregnancy can 
be offered to the parents. If the pregnancy is not terminated, the consultations of neurosur-
geon, neonatologist, and medical genetics are recommended [16].
Fetuses with neural tube defects or central nervous system abnormalities typically remain 
active; however, the quality of fetal movement is often different from that in normal fetuses 
[20]. The fetus with an encephalocele did not respond to repeated vibroacoustic stimulation 
(VAS) with a movement or fetal heart rate (FHR) acceleration [25].
3.6.2. Delivery management
When diagnosed prenatally, vaginal delivery may be safe if the lesion is relatively small. Large 
encephaloceles require cesarean section. Neonates with encephalocele should be  delivered at 
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a facility with a level III NICU. Surgical treatment is appropriate in most cases unless the 
encephalocele is massive and there is severe microcephaly or other lethal anomalies. The pro-
cedure basically consists of removing the overlying sac and closing the defect including the 
dural defect [26]. In patients with basal encephaloceles or cerebrospinal fluid (CSF) leakage, 
prompt closure is important to reduce the risk of infection. Patients with hydrocephalus usu-
ally undergo ventriculoperitoneal shunt placement prior to encephalocele repair to prevent 
postoperative CSF leaks.
3.7. Iniencephaly
3.7.1. Pregnancy management
Iniencephaly is a rare, lethal developmental anomaly. Associated malformations occur in 
up to 84% of cases and include hydrocephaly, microcephaly, ventricular atresia, holopros-
encephaly, polymicrogyria, agenesis of the cerebellar vermis, occipital encephalocele, dia-
phragmatic hernia, thoracic cage deformities, urinary tract anomalies, cleft lip and palate, 
omphalocele, and polyhydramnios [20]. The sonographic diagnosis has been made as early 
as 12.5–13 postmenstrual weeks. Detailed sonography or MRI should be performed to verify 
the diagnosis and to search for associated anomalies. If the iniencephaly is diagnosed at 
less than 22–24 weeks of gestation, the termination of the pregnancy can be offered to the 
parents.
3.7.2. Delivery management
The presence of the hyperextended fetal head might cause dystocia. There is no indication for 
aggressive resuscitation of neonates [16].
3.8. Spinal dysraphism and the Arnold-Chiari malformation
3.8.1. Pregnancy management
Assessment for other abnormalities should be performed by the detailed sonography. 
Associated brain abnormalities include hydrocephaly, relative microcephaly, agenesis of 
the corpus callosum, and diastematomyelia. Non-CNS anomalies consist of congenital sco-
liosis or kyphosis and hip deformities [20]. There is a high prevalence of genetic abnormali-
ties among fetuses with NTDs, especially in the presence of other congenital anomalies so 
microarray should be offered. The diagnostic sensitivity of prenatal sonography for detection 
of myelomeningocele in a high risk population is about 97–98% with 100% specificity [27]. 
Determining the site and extent of the spinal lesion is important because these features cor-
relate with neurologic outcome; more severe neurologic dysfunction is associated with higher 
and larger lesions. Sonographic diagnosis of open spina bifida typically occurs during the 
second trimester of the pregnancy.
When the diagnosis of NTD is confirmed, the parents should be offered the opportunity 
to discuss the long-term prognosis for a child with multidisciplinary team (neonatologist, 
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 medical geneticist, pediatric neurologist, pediatric neurosurgeon, pediatric urologist, pedi-
atric orthopedic surgeon). Long-term prognosis is related to the location of the NTD—the 
lower the defect, the better the prognosis [16]. In fetuses with myelomeningoceles, higher 
and larger lesions on MRI were significantly associated with full-time wheelchair use. High 
lesion level was associated with dysphagia. The absence of a covering membrane was asso-
ciated with scoliosis and high-risk bladder dysfunction [28]. If the diagnosis is at less than 
22–24 weeks of gestation, the opportunity of pregnancy termination can be offered to the 
parents. During prenatal counseling, discussion with the parents includes the natural his-
tory of myelomeningocele and the prenatal management decisions, including termination 
of the pregnancy, pursuit of additional prenatal testing, choice of delivery setting, and, 
when applicable, the possibility of fetal surgery. The postnatal management choices are 
also discussed, including surgical closure of the defect and possible need for ventriculo-
peritoneal shunt placement. Longitudinal follow-up after prenatal diagnosis of myelome-
ningocele suggests that approximately 60–70% of pregnancies end in termination or fetal 
demise [29, 30].
• Fetal intervention. Fetal surgery for myelomeningocele can arrest leakage of spinal fluid 
from the back and might therefore prevent or reverse herniation of the hindbrain (Chi-
ari II malformation) and hydrocephalus [31]. Prenatal surgery for myelomeningocele 
reduced the need for shunting and improved motor outcomes at 30 months but was as-
sociated with maternal and fetal risks [32]. These benefits occurred despite a higher risk 
of preterm delivery and pulmonary complications among infants undergoing fetal sur-
gery and of obstetrical complications, including placental abruption, dehiscence of the 
hysterotomy site, and maternal transfusion at delivery [32, 33]. Because fetal surgery is 
associated with risks of fetal and maternal complications, the family should be informed 
about the option of prenatal surgery, including the uncertainty regarding whether the 
risks of the procedure are outweighed by the potential benefits, particularly since long-
term outcomes are not clearly known. Women with pregnancies complicated by fetal my-
elomeningocele who meet established criteria for in utero repair should be counseled in a 
nondirective fashion regarding all management options, including the possibility of open 
maternal-fetal surgery. Maternal-fetal surgery for myelomeningocele repair should be of-
fered only to carefully selected patients at facilities with an appropriate level of personnel 
and resources [34].
3.8.2. Delivery management
For infants with a prenatal diagnosis of myelomeningocele who do not undergo fetal inter-
vention, delivery should occur at a center with a level III NICU, pediatric neurosurgery 
services, and other personnel experienced in the neonatal management of these infants. 
Latex-free gloves and equipment should be used during delivery and subsequent care of the 
infant because patients with myelomeningocele are at risk for developing life-threatening 
latex allergy.
Term delivery is preferable, but increasing ventriculomegaly with macrocephaly on prenatal 
ultrasound may necessitate preterm delivery. Fetuses presenting in the breech position are 
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typically delivered by cesarean section. The optimal route of delivery of a fetus presenting 
in the vertex position is controversial. Vaginal delivery is reasonable if the head is normal 
size, the meningocele is unlikely to cause dystocia, and there are no obstetrical indications for 
cesarean [35].
3.9. Fetal cerebral ventriculomegaly
3.9.1. Pregnancy management
Fetal cerebral ventriculomegaly is a relatively common finding on second trimester obstetri-
cal ultrasound examination. Many cases are associated with other abnormal findings, but 
in some fetuses, ventriculomegaly is the only abnormality [36]. Most children with isolated, 
mild ventriculomegaly have a normal outcome. The risk of abnormal outcome increases with 
the severity of ventriculomegaly, progression of ventriculomegaly, and presence of other 
anomalies. After ventriculomegaly is identified, further management involves identifying 
whether additional abnormalities (CNS and non-CNS) are present, diagnostic evaluation for 
the most common causes of ventriculomegaly, and counseling patients about the prognosis 
and potential pregnancy interventions. If the etiology of ventriculomegaly has been deter-
mined (e.g., trisomy, CMV) or associated malformations are identified, the parents can be 
given more specific information. Before viability, pregnancy termination is an option and 
should be offered.
• Assessment for associated CNS and extra-CNS anomalies. Associated abnormalities have 
been reported in 10–76% of cases [36, 37]. Identification of these abnormalities helps in 
determining the cause of ventriculomegaly and the prognosis. Fetal MRI can be used to 
identify underlying CNS abnormalities not detected by sonography. Because CNS infec-
tion can result in ventriculomegaly, it is important to look for characteristic sonographic 
findings of fetal infection, such as intracerebral and periventricular calcifications, hepatic 
calcifications, hepatosplenomegaly, ascites, and polyhydramnios.
• Evaluation for infection. Tests for CMV infection, toxoplasmosis, Zika virus infection, and 
lymphocytic choriomeningitis virus infection should be recommended. Sporadic cases of 
ventriculomegaly associated with other viruses have also been reported (mumps entero-
virus 71 (EV71), parainfluenza virus type 3, parvovirus B19) [36]. PCR for CMV and toxo-
plasmosis should also be obtained when amniocentesis is performed. If the patient de-
clines amniocentesis or karyotyping has been done previously, maternal serology is used 
to identify an infectious etiology. However, serology is neither as sensitive nor as specific 
as PCR on amniotic fluid, thus amniotic fluid PCR is the preferred method of evaluation 
for infection [36].
• Genetic assessment. Fetuses with apparently isolated mild ventriculomegaly in 4.7% were 
found to have an abnormal karyotype [38]. The risk is higher with severe ventriculomegaly 
or associated abnormalities.
• Follow-up evaluation. Follow-up ultrasound examinations are obtained to look for regres-
sion or progression of ventriculomegaly and to re-evaluate for anomalies. Early isolated 
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mild ventriculomegaly may resolve by the third trimester; progression occurs in 16% of 
cases and has been associated with a worse outcome [36, 39]. Follow-up ultrasounds have 
detected fetal abnormalities not detected on the initial scan in 13% of cases [36]. Therefore, 
at least one additional detailed ultrasound examination should be performed between 28 
and 34 weeks of gestation to look for CNS and non-CNS abnormalities and regression or 
progression of dilatation. Antepartum fetal testing has no proven benefit in pregnancies 
with isolated fetal ventriculomegaly in the absence of other findings, such as intrauterine 
growth restriction or oligohydramnios.
• Fetal intervention. Intrauterine treatment with ventriculoamniotic shunting was performed 
in the 1980s. The expert consensus at that time was that these results did not represent an 
improvement in outcome over expectant management, which led to a de facto moratorium 
on such procedures [40]. At present, however, such procedures are investigational [36].
3.9.2. Delivery management
Ventriculomegaly may or may not be accompanied by macrocephaly. Most infants with ven-
triculomegaly have a normal head circumference (HC), there is no increased risk of cepha-
lopelvic disproportion, and cesarean delivery is not required except for standard obstetric 
complications. When the HC exceeds 40 cm, abdominal delivery should be considered.
Cephalocentesis, which almost always results in fetal death, is rarely used to decompress 
the head, allow vaginal delivery, and avoid maternal morbidity from cesarean delivery, in 
cases in which the neurological prognosis is so dismal (trisomy 13 or 18 or lethal co-existent 
anomalies) [41].
4. Fetal thoracic anomalies
4.1. Congenital diaphragmatic hernia
4.1.1. Pregnancy management
Over the past 20 years, prenatal detection of congenital diaphragmatic hernia (CDH) has 
improved worldwide, reaching up to 60% in Europe. Pulmonary hypoplasia and persistent 
pulmonary hypertension are the two main determinants of neonatal mortality and morbidity, 
so new tools have been focused on their evaluation. Fetal surgery for severe cases requires 
proper evaluation of the prognosis of fetuses with CDH [42]. After CDH is identified, further 
management involves referral to a tertiary center for confirmation of the diagnosis, assess-
ment of severity and associated anatomic and genetic abnormalities, multidisciplinary coun-
seling about options and prognosis, and planning further management. Management may be 
expectant with prenatal referral to a center with expertise in caring for these infants, termina-
tion of pregnancy, or fetal intervention [43]. The mean gestational age at diagnosis is about 
24 weeks. Polyhydramnios may be present due to esophageal compression. Hydrops fetalis 
can occur from mediastinal shift and compression of the great vessels.
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• Assessment for associated anomalies. Ultrafast fetal MRI to look for associated abnormali-
ties and liver herniation and to estimate lung volumes and fetal echocardiography should 
be performed.
CDH can be an isolated anomaly, part of a syndrome, or nonsyndromic but associated with 
other abnormalities. Approximately 50–70% of cases of CDH are isolated. Pulmonary hypo-
plasia, intestinal malrotation, and cardiac dextroposition are due to the hemodynamic or 
mechanical consequences of CDH; thus, they are usually considered part of the CDH sequence 
and do not negate the designation ‘isolated CDH.’ The other 30–50% of cases are called ‘com-
plex’, ‘nonisolated’, or ‘syndromic’ CDH (CDH+) because they are associated with additional 
abnormalities, including major structural malformations, chromosomal abnormalities, and/
or single gene disorders. Malformations occur in all major organ systems, with no specific 
pattern [43]. An underlying syndrome is present in approximately 10% of CDH cases occur-
ring with associated anomalies [43]. CDH is a prominent finding in the Fryns phenotype; 
facial dysmorphology, distal digital hypoplasia, and cardiac/renal/brain anomalies can also 
occur. CDH and diaphragmatic eventration are also an occasional component of many other 
syndromes, including Apert, Killian/Teschler-Nicola (Pallister-Killian), CHARGE, Coffin-
Siris, Goltz, Perlman, Swyer, Brachmann-Cornelia De Lange, Goldenhar sequence, Beckwith 
Wiedemann, Simpson-Golabi-Behmel, Donnai-Barrow, Mathew-Wood, Jarcho-Levin, Fraser, 
Stickler, Pierre Robin, and others [43, 44].
Associated anomalies are most common with bilateral CDH and in stillborn infants with 
CDH, where the prevalence is as high as 95% [43]. Anomalies in stillborn infants with CDH 
primarily consist of neural tube defects (anencephaly, myelomeningocele, hydrocephalus, 
and encephaloceles) and cardiac defects (ventriculoseptal defects, vascular rings, and coarcta-
tion of the aorta) [45].
• Genetic assessment. Chromosomal anomalies are identified in 10–20% of prenatally iden-
tified cases; the most common diagnoses include trisomies 18, 13, and 21 [43, 46]. Other 
karyotype abnormalities, such as monosomy X, tetrasomy 12 p (isochromosome 12p), par-
tial trisomy 5, partial trisomy 20, and polyploidies, have also been reported [43, 47].
• Evaluation of prognostic factors for survival. Prognosis is worse in the setting of an abnor-
mal chromosomal microarray, severe associated anomalies, right-sided defect, liver hernia-
tion, and lower fetal lung volume [43, 48]. The lung area to head circumference ratio (LHR) 
is more predictive of morbidity than mortality. A large defect is more likely to result in 
pulmonary hypoplasia and death than a small defect. The size of the defect is not measur-
able prenatally, so the presence of liver herniation and fetal lung volume measurements 
serves as a proxy for defect size [43]. Several other clinical findings for survival have not 
been confirmed (early gestational age at diagnosis, severe mediastinal shift, polyhydram-
nios, a small lung-thorax transverse area ratio, left ventricle/right ventricle index, left heart 
hypoplasia, and the stomach in the chest) [43].
Liver herniation is the most reliable prenatal predictor of postnatal survival. A systematic 
review of studies that used ultrasound or MRI to evaluate outcome of fetuses with liver her-
niation included 710 fetuses and reported significantly higher survival rate in fetuses without 
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herniation (74% versus 45% with herniation) [49]. Ultrafast fetal MRI using rapid HASTE tech-
nique is the most powerful tool to accurately demonstrate liver herniation [50]. Ultrasound 
can be useful; in particular, color flow Doppler can visualize bowing of the ductus venosus 
to the left of the midline or coursing of the portal branches or hepatic veins to the lateral seg-
ment of the left lobe above the diaphragm; however, ultrasound has not always accurately 
demonstrated liver herniation in the fetus with left-sided CDH [43, 50].
Absolute or relative fetal lung volume appears to be useful for predicting survival, but the 
optimum equation has not been determined [43, 51]. Several small studies have suggested 
that postnatal survival is poor when fetal lung volume measured by MRI is less than about 
30% of expected lung volume for gestational age and especially when <15% [43]. Lung vol-
ume can also be assessed using 3D sonography, but MRI may be more reliable.
Right- versus left-sided lesion. Right-sided CDH have a poorer outcome than that reported 
for fetuses with left-sided CDH with similar lung size before birth [52].
Lung area to head circumference ratio (LHR) is an estimate of contralateral lung size and 
mediastinal shift at the level of the atria on transverse scan of the fetal thorax. Although 
there is a significant correlation between LHR and survival, the lower limit of LHR com-
patible with survival is dropping, so the test is less predictive than in the past [43, 53]. 
LHR is now more indicative of morbidity than mortality [43]. In left CDH, the LHR is 
calculated using a two-dimensional perpendicular linear measurement of right lung area 
(in square millimeters) divided by the head circumference (in millimeters) to minimize 
lung size differences owing to gestational age [43]. Measurement of fetal lung volume is 
much more useful than LHR in fetuses without liver herniation [54]. Because lung growth 
is four times greater than head growth during pregnancy [55], some experts suggest that 
the LHR should be expressed as a function of gestational age (observed [O]/expected [E] 
LHR). The O/E LHR can be calculated using a formula specifically developed for this mea-
suring technique and has been validated in fetuses with unilateral isolated CDH in terms 
of both mortality and morbidity [53]. An online calculator is available (www.totaltrial.eu). 
O/E LHR is considered extreme if <15%, severe at 15–25%, moderate at 26–35%, and mild 
if 36–45% [44].
• Fetal interventions. Fetal endoscopic tracheal occlusion (FETO) is an investigational pro-
cedure for treatment of isolated severe congenital diaphragmatic hernia to prevent or re-
verse pulmonary hypoplasia and restore adequate lung growth for neonatal survival. The 
rationale for this approach is that the dynamics of fetal lung fluid can dramatically affect 
lung growth [43]. Under normal circumstances, the lungs are net producers of amniotic 
fluid with lung liquid volume and intratracheal pressure maintained at constant values 
by fetal laryngeal mechanisms [43]. Prenatal tracheal occlusion (TO) obstructs the normal 
egress of lung fluid during pulmonary development, increasing transpulmonic pressure 
and resulting in large fluid-filled lungs. Lack of lung expansion 2 and 7 days after TO is a 
poor prognostic sign and may indicate that the occlusion is inadequate [56]. Techniques 
to achieve minimally invasive fetoscopic reversible fetal TO have been developed to de-
crease the risks of preterm labor and restore surfactant deficiency [43]. A percutaneous 
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procedure under local anesthesia, with fetal pain relief and immobilization, is possible 
[57]. Fetal TO in severe CDH is associated with a high incidence of PPROM and preterm 
delivery but a substantial improvement in survival. Smaller and fewer trocars were uti-
lized in another study, resulting in a lower rate of preterm rupture of membranes and 
preterm delivery [58].
Important factors in offering prenatal therapy continue to be, first and foremost, determining 
which fetuses have a poor prognosis. The optimal timing, duration, and release of occlusion 
in humans are not known. The Eurofetus group has had early success with fetal TO [59]. The 
insertion of the balloon at 26–28 weeks for severe cases and 30–32 weeks for moderate cases 
is recommended. Ideally, the occlusion is reversed before delivery at 34 weeks, usually by 
fetoscopy or ultrasound-guided puncture.
The FETO Consortium subsequently reported the outcome of 210 consecutive procedures 
[57]. Compared with the outcome of expectantly managed cases enrolled in their registry, 
FETO increased survival in severe cases with left CDH from 24–49% and right CDH from 
0–35% (p < 0.001) [57]. However, at least 10 deaths attributed to difficulty with balloon 
removal before or at the time of emergent delivery have been reported [60]. The Eurofetus 
consortium also noted that preterm delivery, usually due to premature rupture of mem-
branes, is a common complication and occurred in 17% of cases within 3 weeks of the pro-
cedure [43]. FETO has resulted in few clinical side effects on the developing trachea, except 
in very early occlusions and complications arising at the time of removal [43]. Neonates 
have tracheomegaly, which does not seem to have a clinical impact other than a barking 
cough on effort. The Tracheal Occlusion to Accelerate Lung Growth (TOTAL) trial is ongo-
ing in Europe and feasibility studies for FETO are ongoing at several North American fetal 
centers [43].
• Follow-up assessment. There are no data from well-designed studies on which to base 
recommendations for antepartum obstetrical management. The intrauterine risk of fetal 
demise is 2–8%, but higher when other anomalies are present [43]. Twice-weekly nonstress 
testing or biophysical profile testing at 33–34 weeks should be offered [43]. Ultrasound 
examinations at 28, 30, 32, and 34–35 weeks of gestation to assess fetal growth and am-
niotic fluid volume. Polyhydramnios may develop at 28–32 weeks if fetal swallowing is 
impaired, and oligohydramnios may develop if the fetus is compromised later in gestation. 
Signs of secondary complications, such as particulate meconium in fluid, dilated stom-
ach in chest, effusions, or ascites, may lead us to deliver the fetus preterm. Fetal growth 
restriction or oligohydramnios may also lead us to deliver the fetus early. Antenatal glu-
cocorticoids are given, if appropriate, to decrease morbidity from preterm delivery as for 
standard indication [43].
4.1.2. Delivery management
The optimal mode and gestational age for delivery of an infant diagnosed prenatally with 
CDH is uncertain [43]. A planned induction of labor between 38 and 39 weeks of gestation 
is suggested so that the fetus is monitored from the earliest stage of labor and so pediatric 
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surgery and neonatology services are prepared to care for the infant. The fetal lung maturity 
prior to delivery should not be assessed [43]. Up to 50% of cases require extracorporeal mem-
brane oxygenation (ECMO); therefore, the delivery at a tertiary center with ECMO capability 
is recommended [43]. Cesarean delivery is performed for standard obstetrical indications [43].
4.2. Congenital pulmonary airway malformation
4.2.1. Pregnancy management
Prenatal diagnosis of congenital pulmonary airway malformation (CPAM) has increased with 
widespread use of prenatal ultrasonography and magnetic resonance (MR) imaging. When 
CPAM is diagnosed, the quantitative evaluation helps predict the prenatal course of the dis-
ease and should include the following [61]:
1. Congenital pulmonary airway malformation volume ratio (CVR)—Obtained by calculat-
ing the volume of the lung mass using the formula for the volume of an oval and normaliz-
ing it by gestational age. To normalize by gestational age, the lung mass volume should be 
divided by the head circumference. CVR = height x anteroposterior diameter x transverse 
diameter x 0.52 (constant)/head circumference.
2. Mass-to-thorax ratio (MTR)—The ratio between the transverse diameter of the mass and 
the transverse diameter of the thorax. It is measured on an axial image of the chest, where 
the four-chamber view of the heart is present.
3. Observed to expected lung-to-head ratio (o/e LHR)—Initially described as a predictor of 
outcome in congenital diaphragmatic hernia.
The prenatal course depends on the gestational age, size of the mass, amount of mediasti-
nal shift, fetal hemodynamics, and associated anomalies, more than the type of lesion [61]. 
About 50% of masses persist to delivery [62]. Fifteen percent of these masses decrease in 
size during the late second and the third trimesters; the majority have a relative decrease in 
size due to normal fetal thoracic growth, but a few increase in size [61]. It is difficult to pre-
dict at the time of the initial ultrasound whether lesions will regress, stabilize, or continue 
to grow and lead to significant problems, including hydrops, need for surgical intervention 
or postnatal respiratory assistance, or death. The use of CVR, MTR, and, to a lesser degree, 
o/e LHR helps better identify patients at risk [61, 63]. A CVR >1.6 is predictive of risk for 
hydrops, respiratory distress at birth, and probable need for early surgery [61], whereas a 
CVR <0.91 at presentation predicts a favorable outcome so follow-up examinations can be 
less frequent [61, 63]. A MTR <0.51 suggests the fetus is at low risk for developing compli-
cations [61, 63]. In the absence of hydrops, the prognosis is good with reported live birth 
rates ≥95% [61].
• Assessment for associated anomalies. A comprehensive fetal survey, including fetal echo-
cardiography, should be performed as 10–20% of fetuses with CPAM have associated con-
genital abnormalities, such as esophageal atresia with tracheoesophageal fistula, bilateral 
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renal agenesis or dysgenesis, intestinal atresia, other pulmonary malformations, and dia-
phragmatic, cardiac, central nervous system, and bony anomalies [61]. Fetal echocardiog-
raphy is recommended in all patients at time of diagnosis to rule out congenital cardiac 
anomalies.
• Follow-up assessment. All patients should have serial prenatal follow-up examinations 
every 1 to 4 weeks to assess change in size of the lung mass, change in CVR, and develop-
ment of polyhydramnios and hydrops [61]. The frequency depends on the gestational age 
and CVR. Closer follow-up should be performed in those patients at high risk of develop-
ing hydrops (CVR ≥1.6, age < 26 weeks), whereas the interval between examinations can 
be lengthened if the CPAM is very small, CVR is <0.91 [63]. The presence of hydrops is a 
sign for impending fetal demise and thus it is an indication for fetal intervention [61]. The 
recommendation of proceeding with fetal intervention is based on results from small case 
series showing good survival (>90%) if hydrops resolves [61].
For fetuses greater than 32–34 weeks of age, early delivery with immediate postnatal resection 
is a reasonable option [61]. Ex utero intrapartum therapy (EXIT) has been used to stabilize 
fetuses with large lesions expected to have difficulty breathing at delivery [64].
For gestations between 20 and 32 weeks, several interventions with the goal of improv-
ing fetal hemodynamics and preventing lung hypoplasia have been described and appear 
to improve survival [61]. Drainage procedures are used for CPAMS with dominant cysts, 
while solid masses are treated by resection or ablation. Karyotype analysis is recommended 
prior to initiating fetal therapy [61]. All of the following interventions should be considered 
investigational.
Antenatal corticosteroids are the only medical treatment of CPAM. They are used primarily 
for treatment of microcystic CPAM, since these masses cannot be managed by minimally 
invasive procedures, but have been used for macrocystic disease, as well [61]. In uncon-
trolled studies, maternal steroid administration appeared to reverse hydrops and improve 
outcome [61]. Multiple courses of antenatal betamethasone for high-risk fetal CPAMs often 
result in favorable short-term outcomes without the need for open fetal resection. The 
fetuses who did not respond to a first course of steroids stabilized or improved (e.g., reduc-
tion in lesion size, resolving hydrops) after receiving two to four courses of therapy [65]. The 
median interval between the first and second courses of steroids was about 2 weeks (range 
1–6 weeks) [61].
• Fetal intervention. Successful fetal surgery depends on surgical experience, optimal ma-
ternal anesthesia, uterine relaxation, hysterotomy, fetal exposure, and intraoperative fetal 
monitoring.
4.2.2. Drainage procedures
• Thoracentesis—For fetuses with large pleural effusions, thoracentesis to prevent pulmo-
nary hypoplasia is possible, but rapid reaccumulation of fluid limits its usefulness [61]. The 
fluid should be sent for cell count to exclude an infectious etiology [61].
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• Cyst aspiration should decompress a large macrocyst and reverse the mediastinal shift. 
Although fluid reaccumulation is common and limits its usefulness [61].
• Thoracoamniotic shunt provides a therapeutic option for select fetuses with large macro-
cystic lung lesions or pleural effusion at risk for hydrops and/or pulmonary hypoplasia. 
Survival following shunting depends on gestational age at birth, reduction in mass size, 
and hydrops resolution [66]. Complications include displacement or malfunction of the 
catheter, thrombus occlusion of the catheter, fatal fetal hemorrhage, procedure-related ab-
ruptio placentae, premature rupture of membranes, and preterm labor [61].
4.2.3. Surgical resection
For solid or mixed solid/cystic CPAM with a large solid component, in-utero open resection 
has been successfully performed. Following resection, hydrops resolves over 1 to 2 weeks with 
reversal of the mediastinal shift over 3 weeks [61]. Maternal-fetal surgery requiring hyster-
otomy appears to be associated with an increased risk of premature labor, premature rupture 
of membranes, and subsequent pregnancy (uterine dehiscence or rupture) [61]. Percutaneous 
laser ablation of solid CPAM has been reported in only a few case reports and further research 
is warranted [61].
4.2.4. Sclerotherapy
A single study described fetal sclerotherapy in three patients under 26 weeks with CPAM 
and hydrops, severe mediastinal shift, and polyhydramnios [67]. Sclerotherapy was per-
formed with percutaneous injection of Ethamolin (ethanolamine oleate) or Polidocanol (aeth-
oxysklerol) into the mass under ultrasound guidance using a 22-gauge needle [61]. Resolution 
of hydrops and of the mass effect was observed in all cases. The patients were delivered at 
term without complications. Further studies are indicated to assess the risks and benefits of 
this innovative technique [67].
4.2.5. Delivery management
If the lung mass has resolved or is small with no mediastinal shift or hydrops, CPAM itself 
is not an indication for early delivery or cesarean delivery [61]. Neonatal respiratory prob-
lems would be unlikely, but the delivery should be recommended in a tertiary care center. 
For fetuses with large masses that cause mediastinal shift and/or hydrops, delivery should 
be planned for a tertiary care center with an intensive care nursery capable of resuscitation 
of a neonate with respiratory difficulties, including capability of extracorporeal membrane 
oxygenation (ECMO), and with pediatric surgeons experienced in care of these infants [61]. If 
hydrops develops after 32 weeks of gestation, early delivery is recommended, possibly with 
the use of EXIT [61]. In EXIT, the fetus is partially delivered and intubated without clamp-
ing the umbilical cord. Uteroplacental blood flow and gas exchange are maintained by using 
inhalational agents to provide uterine relaxation and amnioinfusion to maintain uterine vol-
ume. This provides time for resection of the lung mass prior to complete delivery of the infant 
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in rare instances or, more often, cannulation for extracorporeal membrane circulation, thus 
creating a controlled situation for delayed removal of the CPAM. Overall fetal survival of 90% 
has been reported [61].
4.3. Bronchopulmonary sequestration
4.3.1. Pregnancy management
Bronchopulmonary sequestration (BPS) is usually a small lesion and decreases in size in late 
gestation in about 75% of cases [68].
• Assessment of additional anomalies and genetic evaluation. When a lung mass is first iden-
tified, thorough assessment for additional anomalies is necessary. Intralobar sequestration 
is not associated with an increased risk of additional anomalies [68]. Extralobar BPS is 
associated with anomalies in up to two-thirds of cases [68]. These anomalies include chest 
wall and vertebral anomalies hindgut duplications, diaphragmatic hernia, congenital heart 
disease, and renal and intracranial abnormalities [68]. The incidence of chromosomal ab-
normalities is not increased above baseline in fetuses with BPS alone [68]. Karyotype analy-
sis is recommended prior to initiating fetal therapy.
Parents should be counseled about the possible course of the BPS during pregnancy. At ini-
tial presentation in the early midtrimester, it is difficult to accurately predict what the out-
come will be for an individual fetus, but some predictions are possible, e.g., a large BPS with 
hydrops in the second trimester is likely to do poorly [68].
• Follow-up assessment. All patients should have serial prenatal follow-up examinations to 
assess change in size of the lung mass and development of hydrops [68]. The frequency 
depends on the size of the lesion. The larger lesions should be followed more closely. The 
presence of hydrops is a sign of impending fetal demise and an indication for fetal inter-
vention [68]. This recommendation is based on results from small case series showing high-
er survival rates if hydrops resolves [68]. Because hydrops is uncommon, fetal intervention 
is rarely required and is warranted only in cases where the fetus is severely compromised 
and remote from term. For fetuses greater than 32–34 weeks of age, early delivery with im-
mediate postnatal resection is a reasonable option [68].
For gestations between 20 and 32 weeks, several interventions with the goal of improving fetal 
hemodynamics and preventing lung hypoplasia have been described and appear to improve 
survival [69]. These interventions should only be undertaken at centers experienced in fetal 
surgery. Prenatal intervention requires extensive counseling to the parents on the potential 
risks versus benefits of surgery.
• Fetal intervention. If the BPS is solid with a large pleural effusion, thoracentesis to prevent 
pulmonary hypoplasia is possible, but rapid reaccumulation of fluid limits its usefulness. 
It can be used as a temporizing maneuver to provide prognostic information about the pos-
sible result from placement of a thoracoamniotic shunt [68]. The fluid should be sent for cell 
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count to exclude an infectious etiology [68]. Complications of shunts include displacement 
or malfunction of the catheter, thrombus occlusion of the catheter, fatal fetal hemorrhage, 
procedure-related abruptio placentae, premature rupture of membranes, and preterm la-
bor [68]. There is also a risk of trauma to the fetal chest wall, especially if the procedure is 
performed before 20 weeks [68].
• In-utero open resection, percutaneous laser ablation of the feeding vessel has been success-
fully performed in several small studies [68]. Percutaneous ultrasound-guided fetal sclero-
therapy has also been described [68]. Sometimes two procedures were necessary.
4.3.2. Delivery management
If the lung mass has resolved or is small with no mediastinal shift or hydrops, BPS itself is not 
an indication for early delivery or cesarean delivery [68]. Neonatal respiratory problems would 
be unlikely. For fetuses with large masses that cause mediastinal shift and/or hydrops, delivery 
should be planned for a tertiary care center with an intensive care nursery capable of resuscita-
tion of a neonate with respiratory difficulties, including capability of extracorporeal membrane 
oxygenation (ECMO), and with pediatric surgeons experienced in care of these infants [68]. If 
hydrops develops after 32 weeks of gestation, early delivery is recommended, possibly with 
the use of EXIT. In EXIT, the fetus is partially delivered and intubated without clamping the 
umbilical cord. Uteroplacental blood flow and gas exchange are maintained by using inhala-
tional agents to provide uterine relaxation and amnioinfusion to maintain uterine volume. This 
provides time for initiating extracorporeal membrane circulation to stabilize the infant, thus 
creating a controlled situation before resection of BPS in another operating room [68].
4.4. Congenital lobar emphysema
Congenital lobar emphysema (CLE) is a rare congenital malformation and sometimes is 
detected by prenatal ultrasonography. Lung lesions have increased echogenicity and/or a 
cystic appearance and usually can be differentiated from other congenital lung lesions [70]. A 
chest mass may even disappear on prenatal ultrasound and become apparent again on post-
natal evaluation [70]. Predictors of severe respiratory distress or mortality include polyhy-
dramnios, fetal hydrops, and lung to thorax transverse area ratio (L/T value) of less than 0.25 
[70]. Approximately 25% of cases present at birth, 50% by 1 month of age, and nearly all by 6 
months of age. Infants typically have tachypnea and increased work of breathing and often 
have cyanosis. Recurrent pneumonia or poor feeding with failure to thrive are less frequent 
presentations that may occur in milder forms [70].
4.5. Pulmonary agenesis
Any fetus with suspected bilateral pulmonary agenesis should have a detailed sonographic 
assessment to confirm the diagnosis. If the diagnosis is made till periviable pregnancy, the 
pregnancy termination is an option. If the diagnosis is made at a later gestational age, the 
delivery should be planned without monitoring for fetal distress [16].
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5. Congenital abdominal wall defects
5.1. Gastroschisis
5.1.1. Pregnancy management
There is wide variability in the antenatal management of gastroschisis due to a lack of high-
quality evidence to guide clinical practice [71].
• Assessment of associated anomalies. Associated gastrointestinal anomalies and problems 
(e.g., malrotation, atresia, stenosis, perforation, necrosis, volvulus) occur in up to 25% of 
cases [72] and may be related to vascular disruption caused by herniated bowel. Disrup-
tion of the superior mesenteric artery, for example, may lead to volvulus or to “apple 
peel” jejunal-ileal lesions. Meckel’s diverticulum and gallbladder atresia also occur, but 
are less common. Bladder herniation has been reported in 6% of cases, with bowel or uri-
nary tract dilation [73]. Most cases have no extraintestinal abnormalities, approximately 
10% of gastroschisis cases were associated with major unrelated defects, approximately 
2% of cases were part of a recognized syndrome, and cardiac anomalies were detected 
in 2–3% of cases [74]. Oligohydramnios is the most common amniotic fluid abnormality, 
but polyhydramnios may occur, particularly in fetuses with reduced bowel motility or 
obstruction [73].
• Genetic assessment. The prevalence of chromosomal abnormalities in fetuses with isolated 
gastroschisis is not increased above the baseline population risk, so invasive fetal genetic 
testing is not routinely offered. The fetal genetic evaluation is suggested if nongastroin-
testinal structural abnormalities are identified on ultrasound examination. Chromosome 
abnormalities were detected in 1.2% of the total cases, which included isolated and noniso-
lated, and the most frequent abnormalities were trisomy 18, trisomy 13, sex chromosome 
anomalies, and trisomy 21 [73].
• Follow-up assessment. The most common pregnancy complications associated with 
gastroschisis include development of growth restriction (30–60% of cases), intrauter-
ine fetal demise (3–6%), spontaneous preterm birth (30%), and bowel dilation and wall 
thickening (common, frequency depends on diagnostic criteria) [73]. The mechanisms 
causing these adverse outcomes in gastroschisis are unclear. Therefore, pregnancy mon-
itoring is empiric and typically includes serial ultrasound examinations for assessment 
of fetal growth and fetal bowel abnormality and standard tests for antepartum fetal 
surveillance [73].
• Assessment of fetal growth and amniotic fluid volume—serial ultrasound examinations 
every 3 weeks for assessment of fetal growth and amniotic fluid volume (AFV). If growth 
arrest or oligohydramnios is diagnosed, umbilical artery Doppler flow is evaluated [73]. 
A systematic error of birth weight underestimation when using the Hadlock formulas in 
fetuses affected with gastroschisis was found [75]. Siemer and colleagues developed a 
specific formula for estimating fetal weight in fetuses with abdominal wall defects using 
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the biparietal diameter, occipitofrontal diameter, and femur length measurements [76]. 
Oligohydramnios may be related to fetal growth restriction and is a risk factor for cord 
compression and its sequelae. Polyhydramnios is less common, but an important find-
ing because it is often caused by dysfunction of the gastrointestinal tract due to bowel 
atresia [73].
• Assessment of fetal bowel. Gastric dilatation, bowel dilatation, and bowel wall thickening 
have been considered poor prognostic signs by several investigators [73]. If these signifi-
cant changes are observed prior to 34 weeks, a course of glucocorticoids is suggested for 
fetal maturation [73].
• Antepartum fetal surveillance. Fetal growth restriction and amniotic fluid abnormalities 
are commonly accepted indications for increased antepartum fetal surveillance. The pre-
cise timing and frequency of testing is arbitrary [73].
5.1.2. Delivery management
Gastroschisis increases the risk of preterm delivery; delivery should occur in a facility with 
appropriate resources for caring for these neonates. Gastroschisis alone is not an indication 
for preterm intervention or cesarean delivery [73].
The decision on timing of delivery is based on a combination of factors, including gestational 
age, ultrasound findings (fetal growth profile, AFV, appearance of fetal bowel), and fetal 
testing results (NST, BPP, umbilical cord Doppler if fetal growth restriction is present). In 
the absence of standard obstetric indications for abdominal delivery, a trial of labor rather 
than scheduled cesarean birth for most patients is suggested. Cesarean delivery is reason-
able if the liver is significantly herniated because of the theoretic risk of dystocia and trauma. 
Delivery of pregnancies complicated by fetal gastroschisis at 37 or 38 weeks of gestation is 
suggested to minimize neonatal morbidity and mortality and avoid the possibility of term 
(39–40 weeks) stillbirth; however, there is no consensus on the optimum timing of delivery 
of these pregnancies [73].
5.2. Omphalocele
5.2.1. Pregnancy management
Omphalocele and gastroschisis are the most common fetal abdominal wall defects. By the 
end of the first trimester (11–14 weeks), almost all omphaloceles can be detected by prenatal 
ultrasound examination [77].
• Genetic assessment. Multiple chromosomal abnormalities have been reported among fe-
tuses with omphalocele. As many as 60% of omphaloceles not containing liver are associat-
ed with fetal aneuploidy, particularly trisomy 18 or 13 [77, 78]. Fetal genetic studies should 
be offered if omphalocele or related body wall defects are identified prenatally, because of 
the high risk of aneuploidy. It is reasonable to offer amniocentesis for genetic testing for 
Beckwith-Wiedemann syndrome, but this testing is complicated and should be discussed 
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with a geneticist [77]. There is a 10–20% risk of Beckwith-Wiedemann syndrome in fetuses 
with apparently isolated omphalocele on ultrasound.
• Assessment of associated anomalies. Associated abnormalities that occur with increased fre-
quency in these fetuses include additional gastrointestinal abnormalities, cardiac defects (up to 
50% of cases), genitourinary anomalies, orofacial clefts, neural tube defects, defects of the dia-
phragm, polyhydramnios, and growth restriction. Associated syndromes are best categorized 
by upper, middle, and lower midline omphalocele defects. Omphalocele has been associated 
with several syndromes, including Pentalogy of Cantrell (upper midline defect), amniotic band 
sequence, schisis association (at least two of the following defects: neural tube defect, oral cleft, 
omphalocele, diaphragmatic hernia); lower midline defects are associated with OEIS syndrome 
(omphalocele, exstrophy of the bladder, imperforate anus, spinal defects), Shprintzen syndrome, 
Carpenter syndrome, Goltz syndrome, Marshall-Smith syndrome, Meckel-Gruber syndrome, 
otopalatodigital type II syndrome, CHARGE (coloboma, heart defect, atresia choanae, retarded 
growth and development, genital abnormality, and ear abnormality) syndrome, and Beckwith-
Wiedemann syndrome (hallmark features: macroglossia, gigantism, omphalocele) [77].
• Follow-up obstetrical care. The serial ultrasound examination every 3–4 weeks to evaluate 
fetal growth is recommended. When growth is appropriate and amniotic fluid volume is 
normal, weekly nonstress testing or biophysical profile monitoring at 32 weeks of gesta-
tion to assess fetal well-being are recommended, as these pregnancies appear to be at in-
creased risk of late fetal death [79]. Fetal growth restriction and preterm delivery are not 
uncommon in pregnancies complicated by an omphalocele, particularly with associated 
abnormalities [77]. Nonreassuring fetal testing and/or cessation of fetal growth at or near 
term is an indication for early delivery. A systematic error of birth weight underestimation 
in fetuses affected with omphalocele was found, the same situation as discussed in fetuses 
with gastroschisis. Intrauterine growth restriction in fetuses with abdominal wall defects is 
predictive of an increased risk of adverse neonatal outcome [77].
5.2.2. Delivery management
Delivery should be planning at a tertiary care center. In the absence of standard indications 
for early delivery, it is reasonable to await spontaneous labor or achieve 39 weeks of gesta-
tion. Preterm birth offers no advantage to affected neonates and is associated with increased 
morbidity and mortality. There is no evidence that cesarean delivery improves outcome in 
uncomplicated omphalocele; surgery should be reserved for usual obstetric indications [77]. 
However, some pediatric surgeons have recommended cesarean delivery for fetuses with 
giant omphaloceles (defined as an omphalocele containing >75% of the liver and defect 
greater than 5 cm) in an attempt to avoid dystocia, rupture, infection, and hemorrhage [80]. 
Visceral trauma has also been reported after cesarean delivery [77].
5.3. Bladder exstrophy
Often the diagnosis of bladder exstrophy is made by prenatal ultrasound and, in some cases, 
may be confirmed by MRI. In the event that a prenatal diagnosis is not made, the diagnosis 
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should be clinically apparent and recognizable at birth in the delivery room [81]. If a prenatal 
diagnosis is not made, the diagnosis of bladder exstrophy should be clinically recognizable 
at delivery. A careful physical examination will differentiate bladder exstrophy from other 
congenital anomalies that involve abdominal wall defects, such as omphalocele, gastroschisis, 
and cloacal exstrophy.
Following the prenatal diagnosis of bladder exstrophy, prenatal care includes the following 
[16, 81]:
1. Education and counseling of the parents, touring the neonatal intensive care unit, meeting 
the pediatric urologic care team, and allowing the expectant parent(s) the opportunity to 
interact with other families with a child with bladder exstrophy.
2. Preparation for delivery. In many tertiary centers, one option for planning initial surgical 
management is an induced vaginal delivery that is scheduled in late gestation with coordi-
nation with an on-site pediatric urology service. This approach facilitates bladder closure 
within 72 hours of life.
The cesarean delivery should be reserved for obstetrical complications.
5.4. Body stalk anomaly and cloacal exstrophy
• Body stalk anomaly (also called limb-body wall complex) is a massively disfiguring and 
generally lethal malformation of the thorax and/or abdomen, often associated with limb 
defects. The intrathoracic and abdominal organs lie outside the abdominal cavity and 
are contained within a sac composed of amnioperitoneal membrane attached directly to 
the placenta. The umbilical cord may be totally absent or extremely shortened. Severe 
kyphoscoliosis is often present. Termination of pregnancy is usually offered since the 
abnormality is generally considered lethal [82]. However, repair has been performed in 
rare cases [82]. If the pregnancy is continued, vaginal delivery is recommended given the 
highly lethal nature of this disease, assuming there are no maternal contraindications to 
vaginal delivery. In this setting, the patient should be extensively counseled on the like-
lihood of neonatal demise, as well as the severe morbidity associated with a successful 
repair [82, 83].
• Cloacal exstrophy. The accuracy of sonographic diagnosis appears to be less than 25% due 
to the rarity of the disorder and the wide spectrum of anatomic variants, which depend 
upon the degree of cloacal septation completed. Fetal genetic studies during the initial 
evaluation can be useful, although cloacal exstrophy has not been reported to be associ-
ated with specific aneuploidies. The chromosomal findings, which will include gender, 
may influence the decision to terminate the pregnancy, perform a cesarean delivery for 
fetal indications, or initiate a series of corrective operations in the newborn period [41]. 
Although there are no studies of the optimum route of delivery for this rare disorder, ce-
sarean delivery is generally reserved for standard obstetric indications. The umbilical cord 
should be clamped or ligated carefully to avoid injury to proximate structures. At delivery, 
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 saline-soaked sterile dressings should be applied over the exposed bladder and bowel mu-
cosa and covered with plastic wrap to minimize insensible fluid and heat loss. Survival 
rates of 80–100% have been reported, but quality of life (e.g., bowel, urinary, and sexual 
function) is a concern [82].
6. Congenital anomalies of the kidney and urinary tract
6.1. Pregnancy management
Congenital anomalies of the kidney and urinary tract (CAKUT) constitute approximately 
20–30% of all anomalies identified in the prenatal period [84]. Defects can be bilateral or 
unilateral, and different defects often coexist in an individual child. In general, the optimal 
timing recommended for a screening antenatal ultrasound is between 16 and 20 weeks of 
gestation because of the following factors at this gestational age. Counseling of families 
with fetuses with CAKUT should be universally available. If the fetal prognosis is poor, 
as determined by severe bilateral disease, bilateral RA, oligohydramnios, or unfavorable 
amniotic fluid analysis, legal termination, if possible, can be offered. In all other cases, con-
tinued counseling throughout the pregnancy including discussion of postnatal manage-
ment is required. In particular, discussion with parents regarding their wishes on the level 
of support given to offspring with severe oligohydramnios, who are at risk for lung hypo-
plasia that may be incompatible with life, is helpful in establishing guidelines for initial 
postnatal care [84].
• Assessment of amniotic fluid volume and analysis of biochemical markers are used to eval-
uate fetal renal function. By 20 weeks of gestation, fetal urine accounts for more than 90% 
of the amniotic fluid volume. Thus, a decrease in amniotic fluid volume (oligohydramnios) 
at or beyond the 20th week of gestation is an excellent predictor of abnormal fetal renal 
function and CAKUT [84]. Severe oligohydramnios due to CAKUT either involves both 
kidneys or occurs in a solitary kidney in the fetus. Bilateral renal agenesis (RA) or severe 
dysgenesis, bilateral ureteric obstruction, or obstruction of the bladder outlet or urethra 
can result in severe oligohydramnios as early as 18 weeks of gestation. Because an ad-
equate amniotic fluid volume is critical for lung development, severe oligohydramnios due 
to abnormal fetal renal function in the second trimester can result in lung hypoplasia, a 
potentially fatal disorder.
• Assessment for additional anomalies. Potter’s syndrome consists of a typical facial ap-
pearance characterized by pseudoepicanthus, recessed chin, posteriorly rotated, flat-
tened ears and flattened nose, decreased fetal movement, musculoskeletal features in-
cluding clubfoot and clubhand, hip dislocation and joint contractures, and pulmonary 
hypoplasia.
• Analysis of amniotic fluid. Although oligohydramnios is the most reliable predictor of 
abnormal fetal renal function, its absence does not assure normal fetal renal function. 
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Because amniotic fluid is predominantly composed of fetal urine, measurement of bio-
chemical markers contained in amniotic fluid (fetal urine) can be used to assess fetal renal 
function [84].
• Follow-up assessment. Repeat antenatal ultrasound examinations are performed to help 
guide management decisions. The timing is dependent on findings on the initial examina-
tion. Fetuses with second trimester hydronephrosis (RPD >4 mm) should undergo repeat 
testing in the third trimester to assess progression and select those who will benefit most 
from postnatal testing. A repeat examination 2–3 weeks later in fetuses with bilateral in-
volvement (or an affected solitary kidney) and at 32–34 weeks of gestation in those with 
unilateral involvement is recommended [85].
• In utero intervention. Although there have been case series of antenatal surgery in fetuses 
with severe hydronephrosis and oligohydramnios, this intervention has not been shown to 
improve renal outcome. These procedures may increase the amount of amniotic fluid, thus 
potentially improving lung development and survival rate. In these rare cases, the proce-
dure should only be performed in select centers with expertise and in infants with severe 
bilateral hydronephrosis, absent of severe renal parenchymal or cystic disease, favorable 
urinary electrolyte levels and osmolality, and normal karyotype [84]. Data are limited on 
whether percutaneous vesicoamniotic shunting compared with conservative observation 
in fetuses with lower urinary tract obstruction improves survival and renal outcome. The 
percutaneous vesicoamniotic shunting should not be routinely performed in fetuses with 
lower urinary tract obstruction [85].
6.2. Delivery management
Cesarean delivery should be reserved for obstetrical indications. The time of delivery depends 
on the fetal well-being and amniotic fluid volume.
7. Esophageal, gastrointestinal, and anorectal atresia
7.1. Pregnancy management
Prenatal sonographic diagnosis of gastrointestinal atresia is challenging since obstruction 
may not become evident sonographically until the late second trimester, after the typical 
time of a fetal anatomic survey (18–20 weeks of gestation). It can also be difficult to differen-
tiate dilated small bowel loops from colon or megaureters sonographically [86]. It is unclear 
whether prenatal diagnosis of esophageal, gastrointestinal, or anorectal atresia improves the 
prognosis. However, early prenatal diagnosis provides an opportunity for parental coun-
seling and preparation, screening for associated anomalies, and the option for pregnancy 
termination or delivery at a setting with appropriate personnel and facilities for newborn 
care [86].
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• Indications for magnetic resonance imaging. MRI may be used to confirm or clarify sus-
pected gastrointestinal abnormalities on ultrasound examination if this information is im-
portant for managing the pregnancy. Fetal bowel is well visualized by MRI and easily 
differentiated from adjacent liver, spleen, kidneys, bladder, and gallbladder. Meconium is 
also well visualized [87]. The normal esophagus, stomach, and duodenum should always 
be filled with T2 hyperintense fluid (amniotic fluid).
• Assessment of additional anomalies and follow-up assessment. Many of these pregnancies 
are complicated by polyhydramnios. After diagnosis, the performance of periodic ultra-
sound examinations to look for any change in the appearance of the atresia or associated 
anomalies and to assess interval fetal growth and amniotic fluid volume is recommended. 
Nonstress tests or biophysical profiles are indicated in pregnancies in which the risk of 
antepartum fetal demise is increased, such as a fetal anomaly associated with growth re-
striction [86].
7.2. Delivery management
Atresia alone is not an indication for cesarean delivery in the absence of a standard obstetric 
indication. However, if the abdominal circumference is much larger than the head circum-
ference, cesarean delivery should be considered due to the risk of fetal abdominal dystocia. 
Delivery should be planned at a center that has an appropriate level of neonatal support.
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